Patents by Inventor Mark McLaughlin

Mark McLaughlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190308878
    Abstract: Systems and methods for producing microcrystalline alpha alane are provided herein. An exemplary process comprises the elimination of the crystallization aid lithium borohydride through the use of excess lithium aluminum hydride or sodium borohydride. Further exemplary processes comprise methods for passivating microcrystalline alpha alane using a weak acid in a nonaqueous solvent solution.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 10, 2019
    Inventors: David Stout, Henry Fong, Elisabeth McLaughlin, Paul E. Penwell, Mark A. Petrie, Robert Wilson
  • Patent number: 10435297
    Abstract: Systems and methods for producing microcrystalline alpha alane are provided herein. An exemplary process comprises the elimination of the crystallization aid lithium borohydride through the use of excess lithium aluminum hydride or sodium borohydride. Further exemplary processes comprise methods for passivating microcrystalline alpha alane using a weak acid in a nonaqueous solvent solution.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: October 8, 2019
    Assignee: Ardica Technologies, Inc.
    Inventors: David Stout, Henry Fong, Elisabeth McLaughlin, Paul E. Penwell, Mark A. Petrie, Robert Wilson
  • Patent number: 10433973
    Abstract: Embodiments herein are generally directed to vertebral implants and implant trials for use with vertebral implant assemblies. In some embodiments, these implants and implant trials may be used in conjunction with corpectomy procedures.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: October 8, 2019
    Assignee: GLOBUS MEDICAL INC.
    Inventors: George Howard, James Himmelberger, Jason Gray, Colm McLaughlin, Noah Hansell, Mark Weiman
  • Publication number: 20190274844
    Abstract: A soft tissue repair system is provided for covering or filling openings in the annulus of an intervertebral disc. The soft tissue repair system uses a single plug or a combination of a first plug and a second plug. The second plug is a flowable plug such as an adhesive material or a material that hardens to a flexible plug material. Each plug is configured to close the opening in the annulus and can be positioned within the opening, over the opening at the exterior surface or over the opening at the interior surface. The plug can also be combined with a clamping mechanism that engages the annulus to secure the plug in the opening.
    Type: Application
    Filed: March 6, 2018
    Publication date: September 12, 2019
    Inventors: Jody L. Seifert, David C. Paul, Sean Suh, Colm Mclaughlin, Marcin Niemiec, Aditya lngalhalikar, Daniel Davenport, Jamie Carroll, Chad Glerum, Edward Dwyer, Noah Hansell, Mark Weiman, Douglas Cahill, Adam Friedrich, Michelle Kofron, Vipin Kunjachan, Ed Reilley, Damien O'Halloran, William S. Rhoda, Brian Malm
  • Publication number: 20190263857
    Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.
    Type: Application
    Filed: October 3, 2018
    Publication date: August 29, 2019
    Inventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
  • Patent number: 10392353
    Abstract: Disclosed herein is a novel process for preparing substituted quinazoline compounds of formula (I) using a hydrogen bonding catalyst.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: August 27, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Cheol K. Chung, Guy R. Humphrey, Zhijian Liu, Mark McLaughlin, Yingju Xu, Younong Yu
  • Patent number: 10376373
    Abstract: Embodiments herein are generally directed to vertebral implants and implant trials for use with vertebral implant assemblies. In some embodiments, these implants and implant trials may be used in conjunction with corpectomy procedures.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: August 13, 2019
    Assignee: Globus Medical, Inc.
    Inventors: George Howard, James Himmelberger, Jason Gray, Colm McLaughlin, Noah Hansell, Mark Weiman
  • Publication number: 20190244204
    Abstract: A general-purpose payment card product is linked to a designated reimbursement account. A payment card authorization request is obtained, with a full amount and a reimbursement eligible amount included therein, based on a transaction with the payment card product at a merchant. In one aspect, a payment card authorization response is returned to the merchant from an issuer of the payment card product, based on the full amount. A funding request is initiated, for the reimbursement eligible amount, from the designated reimbursement account. The payment card product and the designated reimbursement account are managed separately. In an alternative, the authorization request is intercepted by an operator of a payment network. The operator initiates a first operator authorization request for the reimbursement eligible amount, and a second operator authorization request for the full amount less the portion of the reimbursement eligible amount, and returns a coordinated response to the merchant.
    Type: Application
    Filed: February 11, 2019
    Publication date: August 8, 2019
    Inventors: Edward McLaughlin, Mark Wiesman, Matthew Lanford
  • Patent number: 10327917
    Abstract: The present invention provides an expandable fusion device capable of being installed inside an intervertebral disc space to maintain normal disc spacing and restore spinal stability, thereby facilitating an intervertebral fusion. In one embodiment, the fusion device includes a body portion, a first endplate, and a second endplate, the first and second endplates capable of being moved in a direction away from the body portion into an expanded configuration or capable of being moved towards the body portion into an unexpanded configuration. The fusion device is capable of being deployed and installed in both configurations.
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: June 25, 2019
    Assignee: Globus Medical, Inc.
    Inventors: Chad Glerum, Andrew Iott, Mark Weiman, Jody Seifert, Kevin Gahman, Colm McLaughlin, Adam Friedrich
  • Publication number: 20190177693
    Abstract: Disclosed are compositions and methods for ex vivo expansion of tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). Also disclosed are compositions and method for identifying an agent for ex vivo expansion of tumor-infiltrating lymphocytes for use in ACT. Also disclosed are methods for treating cancer using tumor-infiltrating lymphocytes expanded by the disclosed methods.
    Type: Application
    Filed: February 11, 2019
    Publication date: June 13, 2019
    Inventors: Amod A. Sarnaik, Shari Pilon-Thomas, Mark McLaughlin, Hao Liu
  • Publication number: 20190092812
    Abstract: The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).
    Type: Application
    Filed: July 2, 2018
    Publication date: March 28, 2019
    Inventors: Lori Hazlehurst, Christoph Rader, Xiuling Li, Mark McLaughlin
  • Publication number: 20190040104
    Abstract: The current invention pertains to stabilized peptoids or peptoid-peptide hybrids. The peptoids or peptoid-peptide hybrids are stabilized by side chain-side to side chain linkages and/or backbone cyclization. The current invention also provides a positional library scanning method for identification of peptoids or peptoid-peptide hybrids having a desired biological activity.
    Type: Application
    Filed: October 11, 2018
    Publication date: February 7, 2019
    Inventors: Mark McLaughlin, Amod A. Sarnaik
  • Patent number: 10197575
    Abstract: The current invention pertains to stabilized peptoids or peptoid-peptide hybrids. The peptoids or peptoid-peptide hybrids are stabilized by side chain-side to side chain linkages and/or backbone cyclization. The current invention also provides a positional library scanning method for identification of peptoids or peptoid-peptide hybrids having a desired biological activity.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: February 5, 2019
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDA
    Inventors: Mark McLaughlin, Amod A. Sarnaik
  • Publication number: 20190022115
    Abstract: The present invention is directed to 4?-substituted nucleoside derivatives of Formula (I) and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC. The present invention also provides processes for the preparation of 4?-substituted nucleoside derivatives of Formula (I) and derivatives thereof.
    Type: Application
    Filed: September 16, 2016
    Publication date: January 24, 2019
    Applicants: Merck Sharp & Dohme Corp., Merck Sharp & Dohme Limited
    Inventors: Vinay M. Girijavallabhan, Mark McLaughlin, Edward Cleator, Jongrock Kong, Andrew William Gibson, David R. Lieberman, Alejandro Dieguez Vazquez, Stephen Philip Keen, Michael J. Williams, Jeffrey C. Moore, Erika M. Milczek, Feng Peng, Kevin M. Belyk, Zhiguo Jake Song
  • Publication number: 20180362583
    Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.
    Type: Application
    Filed: August 27, 2018
    Publication date: December 20, 2018
    Inventors: Lori Hazlehurst, Mark McLaughlin, Priyesh Jain, William S. Dalton
  • Publication number: 20180346429
    Abstract: Disclosed herein is a novel process for preparing substituted quinazoline compounds of formula (I) using a hydrogen bonding catalyst.
    Type: Application
    Filed: November 18, 2016
    Publication date: December 6, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Cheol K. Chung, Guy R. Humphrey, Zhijian Liu, Mark McLaughlin, Yingju Xu, Younong Yu
  • Patent number: 10131674
    Abstract: The present invention is directed to a process for preparing Substituted Indole Compounds of Formula (I): wherein R1, R2, R3 and R4 are as defined herein. These indole compounds are useful as synthetic intermediates for making inhibitors of HCV NS5A.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: November 20, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Daniel A. DiRocco, Ian Davies, Feng Peng, Mark McLaughlin, Louis-Charles Campeau, Yingju Xu
  • Patent number: 10118942
    Abstract: Disclosed are monoacylated Toll-like receptor 2 ligands which can be used in both the development of targeted agents for the imaging and treatment of pancreatic cancer as well as other cancers, and as an adjuvant for cancer immunotherapy. The monoacylated compounds disclosed herein have a higher binding affinity for TLR2 relative to a known potent diacylated agonists, but only ?½ the bioactivity. Competition of the monoacylated compound with the diacylated compound for binding TLR2 was confirmed. Hence, the reported monoacylated compounds are inhibitors/antagonists of TLR2 activation.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: November 6, 2018
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., The Arizona Board of Regents on behalf of the University of Arizona, University of South Florida
    Inventors: David L. Morse, Josef Vagner, Mark McLaughlin, Robert Gillies, Amanda Huynh, Michael Doligalski
  • Patent number: 10059740
    Abstract: Integrin interaction inhibitors using a beta-turn promoter are described herein. These peptides are useful in treating cancer, such as multiple myeloma, by administering a therapeutically effective amount of the integrin interaction inhibitor. Data show that integrin interaction inhibitors act synergistically or additively interact with anti-proliferative agents such as doxorubicin, SAHA, arsenic trioxide, and etoposide.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 28, 2018
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDA
    Inventors: Lori Hazlehurst, Mark McLaughlin, Priyesh Jain, William S. Dalton
  • Patent number: 10053466
    Abstract: A process for preparing a compound of structural Formula Ia: comprising Boc deprotection with TFA of: ?and reductive amination of:
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: August 21, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Feng Peng, Yonggang Chen, Amude Mahmoud Kassim, Cheng-yi Chen, Mathew Maust, Mark McLaughlin, Michael J. Zacuto, Qinghao Chen, Lushi Tan, Zhiguo Jake Song, Yang Cao, Feng Xu